PeptideSearch

Retatrutide

Tested in people

Get notified when the evidence changes.

It has been tested in people, but it is not an approved medicine. The studies are usually small.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-08-04

Also called LY3437943 / Triple G / GGG tri-agonist

Hits three different hormone targets at once for weight loss. In late-stage human trials, not yet approved.

Watch: what the research shows

Retatrutide: What The Research Actually Shows

Real trials in the best medical journals. Zero approvals anywhere. Everyone taking it is buying grey market.

Official status: Not nominated for 503A compounding · Checked 2026-08-04

Can a doctor prescribe this?

Small pharmacy (503A)
Never put forward to FDA
Large outsourcing facility (503B)
Never put forward to FDA

Still an investigational drug in clinical trials. Not approved and not legal to compound.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 4

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

We'll email you when a new study, trial or status change lands for Retatrutide. Unsubscribe in one click.